The Journal of Neuroscience, April 11, 2007, 27(15):4165-4177; doi:10.1523/JNEUROSCI.5648-06.2007
Previous Article | Next Article 
Cellular/Molecular
A Molecular Basis of Analgesic Tolerance to Cannabinoids
Anke Tappe-Theodor,1 *
Nitin Agarwal,1 *
István Katona,2
Tiziana Rubino,3
Lene Martini,4
Jakub Swiercz,1
Ken Mackie,5
Hannah Monyer,6
Daniela Parolaro,3
Jennifer Whistler,4
Thomas Kuner,7 and
Rohini Kuner1
1Pharmacology Institute, University of Heidelberg, 69120 Heidelberg, Germany, 2Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary, 3Department of Structural and Functional Biology, Pharmacology Section and Neuroscience Center, University of Insubria, 21100 Busto Arsizio, Varese, Italy, 4Ernest Gallo Clinic and Research Center, University of California, San Francisco, San Francisco, California 94608, 5Department of Anesthesiology, University of Washington School of Medicine, Seattle, Washington 98195-6540, 6Department of Clinical Neurobiology, Interdisciplinary Center for Neuroscience, 69120 Heidelberg, Germany, and 7Max Planck Institute for Medical Research, 69120 Heidelberg, Germany
Correspondence should be addressed to Rohini Kuner, Pharmacology Institute, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany. Email: rohini.kuner{at}pharma.uni-heidelberg.de
Clinical usage of cannabinoids in chronic pain states is limited by their central side effects and the pharmacodynamic tolerance that sets in after repeated dosage. Analgesic tolerance to cannabinoids in vivo could be caused by agonist-induced downregulation and intracellular trafficking of cannabinoid receptors, but little is known about the molecular mechanisms involved. We show here that the type 1 cannabinoid receptor (CB1) interacts physically with G-protein-associated sorting protein 1 (GASP1), a protein that sorts receptors in lysosomal compartments destined for degradation. CB1GASP1 interaction was observed to be required for agonist-induced downregulation of CB1 in spinal neurons ex vivo as well as in vivo. Importantly, uncoupling CB1 from GASP1 in mice in vivo abrogated tolerance toward cannabinoid-induced analgesia. These results suggest that GASP1 is a key regulator of the fate of CB1 after agonist exposure in the nervous system and critically determines analgesic tolerance to cannabinoids.
Key words: cannabinoid receptor 1; receptor trafficking; proteinprotein interactions; endocytosis; GASP; spinal nociception
Received Oct. 18, 2006;
revised Feb. 1, 2007;
accepted Feb. 5, 2007.
Correspondence should be addressed to Rohini Kuner, Pharmacology Institute, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany. Email: rohini.kuner{at}pharma.uni-heidelberg.de
This article has been cited by other articles:

|
 |

|
 |
 
D. L. McKinney, M. P. Cassidy, L. M. Collier, B. R. Martin, J. L. Wiley, D. E. Selley, and L. J. Sim-Selley
Dose-Related Differences in the Regional Pattern of Cannabinoid Receptor Adaptation and in Vivo Tolerance Development to {Delta}9-Tetrahydrocannabinol
J. Pharmacol. Exp. Ther.,
February 1, 2008;
324(2):
664 - 673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Thompson, M. Pusch, and J. L. Whistler
Changes in G Protein-coupled Receptor Sorting Protein Affinity Regulate Postendocytic Targeting of G Protein-coupled Receptors
J. Biol. Chem.,
October 5, 2007;
282(40):
29178 - 29185.
[Abstract]
[Full Text]
[PDF]
|
 |
|